BiotechTube

solifenacin succinate suspension + solifenacin succinate tablet

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioavailability of Solifenacin Succinate

Conditions

Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers

Trial Timeline

Sep 1, 2009 → Nov 1, 2009

NCT ID
NCT01015040

About solifenacin succinate suspension + solifenacin succinate tablet

solifenacin succinate suspension + solifenacin succinate tablet is a phase 1 stage product being developed by Astellas Pharma for Bioavailability of Solifenacin Succinate. The current trial status is completed. This product is registered under clinical trial identifier NCT01015040. Target conditions include Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01015040Phase 1Completed

Competing Products

20 competing products in Bioavailability of Solifenacin Succinate

See all competitors
ProductCompanyStageHype Score
ASP015KAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
IpragliflozinAstellas PharmaPhase 1
33
HetrombopagJiangsu Hengrui MedicinePhase 1
33
ABT-450/r/ABT-267AbbViePhase 1
33
ABT-333AbbViePhase 1
33
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2AstraZenecaPhase 1
33
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orallyAstraZenecaPhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
selumetinib 75mg single doseAstraZenecaPhase 1
33
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tubeAstraZenecaPhase 1
33
AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423AstraZenecaPhase 1
33
Fostamatinib + Fostamatinib + Fostamatinib + FostamatinibAstraZenecaPhase 1
33
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcgAstraZenecaPhase 1
33
D1400147 + D14000136 + D14000137 + Epanova®AstraZenecaPhase 1
33
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of waterAstraZenecaPhase 1
33
NKTR-118 + KetoconazoleAstraZenecaPhase 1
33
TEPEZZA + EDPAmgenPhase 1
32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavirPfizerPhase 1
32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332PfizerPhase 1
32

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85